138 related articles for article (PubMed ID: 26045279)
1. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Sanyal AJ
Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
[TBL] [Abstract][Full Text] [Related]
2. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
[TBL] [Abstract][Full Text] [Related]
3. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
4. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
[TBL] [Abstract][Full Text] [Related]
5. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.
Cheng Z; Chen Y; Schnabl B; Chu H; Yang L
J Adv Res; 2024 May; 59():173-187. PubMed ID: 37356804
[TBL] [Abstract][Full Text] [Related]
6. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.
Rinella ME; Sanyal AJ
Nat Rev Gastroenterol Hepatol; 2015 Feb; 12(2):65-6. PubMed ID: 25560844
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease.
Rom O; Liu Y; Chang L; Chen YE; Aviram M
Curr Opin Lipidol; 2020 Apr; 31(2):104-107. PubMed ID: 32132415
[No Abstract] [Full Text] [Related]
8. Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease.
Cho SW
Endocrinol Metab (Seoul); 2024 Apr; 39(2):285-287. PubMed ID: 38693819
[No Abstract] [Full Text] [Related]
9. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
10. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Hameed B; Terrault N
Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
[TBL] [Abstract][Full Text] [Related]
11. Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance.
Shihabudeen MS; Roy D; James J; Thirumurugan K
Mol Cell Endocrinol; 2015 Oct; 414():19-28. PubMed ID: 26188168
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
Nat Commun; 2015 Jul; 6():7629. PubMed ID: 26134028
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Dincses E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X receptor modulators (2011 - 2014): a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic targets for steatohepatitis.
Sanyal AJ
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S46-50. PubMed ID: 26160474
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor.
Xu X; Xu X; Liu P; Zhu ZY; Chen J; Fu HA; Chen LL; Hu LH; Shen X
J Biol Chem; 2015 Aug; 290(32):19888-99. PubMed ID: 26100621
[TBL] [Abstract][Full Text] [Related]
17. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
18. Management of NAFLD: a stage-based approach.
Rinella ME; Sanyal AJ
Nat Rev Gastroenterol Hepatol; 2016 Apr; 13(4):196-205. PubMed ID: 26907882
[TBL] [Abstract][Full Text] [Related]
19. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
[TBL] [Abstract][Full Text] [Related]
20. Nonmedicinal interventions in nonalcoholic fatty liver disease.
Neuman MG; Nanau RM; Cohen LB
Can J Gastroenterol Hepatol; 2015; 29(5):241-52. PubMed ID: 26076224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
